Document Detail


Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
MedLine Citation:
PMID:  16268920     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Malignant pleural mesothelioma is a fatal disease with a mean life expectancy of 6-12 months. Since 1982, we have performed thoracoscopic talc poudrage (TTP) as a primary therapy in mesothelioma patients presenting with pleural effusion. As the survival data for our patients surpassed that of many published series, the patient data was analyzed to determine whether talc poudrage can be considered as a contemporary palliative option. METHODOLOGY: We reviewed all 26 patients with a final diagnosis of malignant pleural mesothelioma from our prospective database of 228 consecutive patients who received thoracoscopy from the same physician for recurrent symptomatic pleural effusion. Patients were followed up until their death. RESULTS: Mean survival after TTP was 23.8 +/- 16.3 months (median 19.4, range 2.9-68). Pleurodesis palliated dyspnoea in all patients. No perioperative deaths and one postoperative complication (pneumonia) occurred. Mean hospital stay was 3.9 +/- 2.7 days. CONCLUSION: TTP remains a safe, low-morbidity, inexpensive primary palliative treatment option for malignant pleural mesothelioma and a valid control arm option for therapeutic trials. TTP is ideal for patients who wish to avoid thoracotomy, long hospital stays and morbidity from multimodality therapy. Prospective randomized studies are needed to compare quality of life and survival after talc poudrage and other therapies.
Authors:
Yossef Aelony; Janis F Yao
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Respirology (Carlton, Vic.)     Volume:  10     ISSN:  1323-7799     ISO Abbreviation:  Respirology     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-04     Completed Date:  2006-02-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616368     Medline TA:  Respirology     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  649-55     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Kaiser Permanente Medical Center, Harbor City, CA 90710, USA. y.aelony@cox.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
California / epidemiology
Dyspnea / etiology,  prevention & control
Female
Humans
Male
Mesothelioma / complications,  mortality,  pathology,  therapy*
Neoplasm Staging
Palliative Care
Pleural Neoplasms / complications,  mortality,  pathology,  therapy*
Pleurodesis*
Proportional Hazards Models
Prospective Studies
Survival Rate
Talc / administration & dosage*
Thoracoscopy
Chemical
Reg. No./Substance:
14807-96-6/Talc

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis.
Next Document:  Leptospirosis and its pulmonary complications.